Skip to main content

Medullary Thyroid Carcinoma

  • Chapter
  • First Online:
Thyroid and Parathyroid Diseases
  • 1147 Accesses

Abstract

Medullary thyroid carcinoma is a part of “multiple endocrine neoplasia” syndromes in 25% of the cases. Surgery is the primary curative treatment modality in the management of medullary thyroid carcinoma. Detection of the presence and the extent of the metastatic disease is important for the appropriate therapy planning. The contribution of two nuclear medicine procedures 18F-FDG PET/CT’ and 68Ga-DOTATATE PET/CT to the management of medullary thyroid carcinoma is presented in this section.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Geller G, Laskin J, Cheung WY, Ho C. A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy. Thyroid Res. 2017;10:6. https://doi.org/10.1186/s13044-017-0041-6.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375:1054–67. https://doi.org/10.1056/NEJMra1501993.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Accardo G, Conzo G, Esposito D, Gambardella C, Mazzella M, Castaldo F, et al. Genetics of medullary thyroid cancer: an overview. Int J Surg. 2017;41(Suppl 1):S2–6. https://doi.org/10.1016/j.ijsu.2017.02.064.

    Article  PubMed  Google Scholar 

  4. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A. 1994;91:1579–83.

    Article  CAS  Google Scholar 

  5. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610. https://doi.org/10.1007/s00259-016-3404-7.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Qualia CM, Brown MR, Ryan CK, Rossi TM. Oral mucosal neuromas leading to the diagnosis of multiple endocrine Neoplasia type 2B in a child with intestinal pseudo-obstruction. Gastroenterol Hepatol (N Y). 2007;3:208–11.

    Google Scholar 

  7. Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MA, Lairmore TC, et al. Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg. 2002;235:648–54.

    Article  Google Scholar 

  8. Naswa N, Sharma P, Suman Kc S, Lata S, Kumar R, Malhotra A, et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Nucl Med Commun. 2012;33:766–74. https://doi.org/10.1097/MNM.0b013e3283541157.

    Article  PubMed  Google Scholar 

  9. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565–612. https://doi.org/10.1089/thy.2008.0403.

    Article  Google Scholar 

  10. Cheng X, Bao L, Xu Z, Li D, Wang J, Li Y. 18F-FDG-PET and 18F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis. J Med Imaging Radiat Oncol. 2012;56:136–42. https://doi.org/10.1111/j.1754-9485.2012.02344.x.

    Article  PubMed  Google Scholar 

  11. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–98.

    Article  CAS  Google Scholar 

  12. Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC. Immunohistochemical detec- tion of somatostation receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol. 2001;54:641–9.

    Article  CAS  Google Scholar 

  13. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumors with the novel radiolabelled somatostatin analog [177Lu-DOTA(0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417–22.

    Article  CAS  Google Scholar 

  14. Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:49–57. https://doi.org/10.1007/s00259-009-1204-z.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yararbaş, Ü., Özcan, Z. (2019). Medullary Thyroid Carcinoma. In: Özülker, T., Adaş, M., Günay, S. (eds) Thyroid and Parathyroid Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-78476-2_62

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-78476-2_62

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-78475-5

  • Online ISBN: 978-3-319-78476-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics